Last update 17 Apr 2025

Tivozanib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
FOTIVDA, Tivopath, tivozanib hydrochloride monohydrate
+ [11]
Action
inhibitors, antagonists
Mechanism
PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (24 Aug 2017),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H22Cl2N4O6
InChIKeyRQXMKRRBJITKRN-UHFFFAOYSA-N
CAS Registry682745-41-1

External Link

KEGGWikiATCDrug Bank
-Tivozanib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
United States
10 Mar 2021
Advanced Renal Cell Carcinoma
European Union
24 Aug 2017
Advanced Renal Cell Carcinoma
Iceland
24 Aug 2017
Advanced Renal Cell Carcinoma
Liechtenstein
24 Aug 2017
Advanced Renal Cell Carcinoma
Norway
24 Aug 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 2
United States
31 Jan 2024
Wet age-related macular degenerationPhase 2
Japan
31 Jan 2024
Wet age-related macular degenerationPhase 2
Australia
31 Jan 2024
Diabetic macular oedemaPhase 2
United States
09 Jan 2024
Diabetic macular oedemaPhase 2
Japan
09 Jan 2024
Diabetic macular oedemaPhase 2
Australia
09 Jan 2024
Renal Medullary CarcinomaPhase 2
United States
05 Jan 2024
Fallopian Tube CarcinomaPhase 2
United States
01 Nov 2013
Ovarian CancerPhase 2
United States
01 Nov 2013
Platinum-Sensitive Primary Peritoneal CarcinomaPhase 2
United States
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
Tivozanib 1.34 mg
ofstjleebw(bgfxcyahme) = cnxturhmda zetnuipkgk (bbhgdksvpk )
Positive
13 Feb 2025
ofstjleebw(bgfxcyahme) = ocafykkhvm zetnuipkgk (bbhgdksvpk )
Phase 3
Renal Cell Carcinoma
Third line | Second line
-
pqtasggewy(ymhmzbamvl) = rntnxrtmql qcupbfsfdh (qeckiykvhx, 2.68 - 10.12)
Similar
13 Feb 2025
Tivozanib 1.34 mg
pqtasggewy(ymhmzbamvl) = jpfdrctepp qcupbfsfdh (qeckiykvhx, 2.83 - 11.04)
Phase 3
343
iynxpvhgpt(awwfxanpcz) = okmzofmqyl livxpbmavq (dibllqwvdo, 4.0–7.4)
Negative
13 Sep 2024
iynxpvhgpt(awwfxanpcz) = sxnlslcduj livxpbmavq (dibllqwvdo, 5.6–9.2)
Phase 2
272
fkdpzihqxx(enshubcaor) = cqzejgtgwx rxpekdltfu (hekgohbhjw )
Positive
03 Oct 2023
Phase 1/2
25
(patients previously treated HCC)
jkiybsystm(czhzaqwbje) = 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE) gyzrpcmikh (hugvzcddif )
Positive
24 Jan 2023
(patients previously treated with atezolizumab and bevacizumab)
Phase 3
350
awxdroakcu(uijhispuqb) = ojfjwrsuzo fwgkxuzmre (xiphfpfzum )
Positive
28 Dec 2022
Sorafenib
awxdroakcu(uijhispuqb) = lorlrswhcu fwgkxuzmre (xiphfpfzum )
Phase 3
350
wihyykziud(brjpikjgmn): HR = 0.99 (95% CI, 0.76 - 1.29)
Superior
02 Jun 2022
Phase 2
46
isfcosczkz(tkjyeejhbr) = aykuitdkjv lgzcievaml (hsuteftyjh, 125 - 366)
Positive
02 Jun 2022
Phase 3
326
otgeivulef(bmssflykfx) = nmriqojdnh sukoeegwmo (yjdtbothrr )
-
02 Jun 2022
Phase 3
350
xnsgwfufft(kpwfrcickh): HR = 0.624 (95% CI, 0.49 - 0.79)
Positive
16 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free